<scp>SGLT2</scp> Inhibitor Might Prevent Atrial Fibrillation Related to Metabolic Syndrome via <scp>TNF</scp> ‐α Signaling Pathway: A Bioinformatic Study
This study provides insights into the potential mechanisms by which SGLT2 inhibitors influence AF pathogenesis in MetS. The findings suggest that targeting the TNF-α signaling pathway may be a promising therapeutic strategy, with further experimental validation needed to confirm these results. <b>Trial Registration:</b> The authors have nothing to report.
Authors
- Seskoati Prayitnaningsih (ORCID: https://orcid.org/0000-0002-7864-3001)
- Mohammad Saifur Rohman (ORCID: https://orcid.org/0000-0001-6461-2223)
- Adhika Prastya Wikananda (ORCID: https://orcid.org/0009-0006-0121-7553)
- Hidayat Sujuti (ORCID: https://orcid.org/0000-0001-8155-0036)
- Ardian Rizal (ORCID: https://orcid.org/0000-0002-9104-5022)
- Fatchiyah Fatchiyah (ORCID: https://orcid.org/0000-0001-6241-9665)
- Anggri Rudianto
Institutions
- University of Brawijaya (ID)
Publication Details
- Journal
- Journal of Arrhythmia
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1002/joa3.70197
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00